| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 47.99% | Barclays | → $28 | Initiates Coverage On | → Overweight |
| 08/09/2023 | 42.71% | Morgan Stanley | $25 → $27 | Maintains | Equal-Weight |
| 05/08/2023 | 32.14% | Morgan Stanley | $26 → $25 | Maintains | Equal-Weight |
| 03/16/2023 | 74.42% | Raymond James | → $33 | Initiates Coverage On | → Outperform |
| 11/04/2022 | 26.85% | Morgan Stanley | $27 → $24 | Maintains | Equal-Weight |
| 10/14/2022 | 32.14% | B of A Securities | $37 → $25 | Downgrades | Neutral → Underperform |
| 10/12/2022 | 42.71% | Morgan Stanley | $35 → $27 | Maintains | Equal-Weight |
| 09/06/2022 | 79.7% | Piper Sandler | $37 → $34 | Upgrades | Neutral → Overweight |
| 08/05/2022 | 95.56% | B of A Securities | $40 → $37 | Downgrades | Buy → Neutral |
| 07/08/2022 | 79.7% | Morgan Stanley | $35 → $34 | Maintains | Equal-Weight |
| 04/27/2022 | 111.42% | Goldman Sachs | → $40 | Initiates Coverage On | → Buy |
| 04/06/2022 | 84.99% | Morgan Stanley | $37 → $35 | Maintains | Equal-Weight |
| 02/22/2022 | 95.56% | Morgan Stanley | $35 → $37 | Maintains | Equal-Weight |
| 10/07/2021 | 84.99% | Piper Sandler | → $35 | Initiates Coverage On | → Neutral |
| 09/01/2021 | 127.27% | B of A Securities | → $43 | Initiates Coverage On | → Buy |
| 08/16/2021 | 84.99% | Morgan Stanley | $33 → $35 | Maintains | Equal-Weight |
| 07/23/2021 | 84.99% | Citigroup | → $35 | Initiates Coverage On | → Buy |
| 07/22/2021 | 84.99% | Citigroup | → $35 | Initiates Coverage On | → Buy |
| 06/15/2021 | 100.85% | JP Morgan | → $38 | Initiates Coverage On | → Neutral |
| 06/11/2021 | 74.42% | Morgan Stanley | → $33 | Initiates Coverage On | → Equal-Weight |
| 06/10/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform |
What is the target price for Organon (OGN)?
The latest price target for Organon (NYSE: OGN) was reported by Barclays on September 21, 2023. The analyst firm set a price target for $28.00 expecting OGN to rise to within 12 months (a possible 47.99% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Organon (OGN)?
The latest analyst rating for Organon (NYSE: OGN) was provided by Barclays, and Organon initiated their overweight rating.
When is the next analyst rating going to be posted or updated for Organon (OGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organon, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organon was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
Is the Analyst Rating Organon (OGN) correct?
While ratings are subjective and will change, the latest Organon (OGN) rating was a initiated with a price target of $0.00 to $28.00. The current price Organon (OGN) is trading at is $18.92, which is within the analyst's predicted range.